PharmaEngine

PharmaEngine Net Debt per Share

The Net Debt per Share of PharmaEngine (4162.TWO) as of Nov 12, 2026 is 0.05 TWD. In the previous year, Net Debt per Share was -24.80 TWD — a change of -100.20% (higher).

Net Debt per Share

0.05TWD

YoY

-100.20%

Last updated:

Net Debt per Share of PharmaEngine is 2024 0.05 TWD. Net Debt per Share of PharmaEngine was 2023 -24.80 TWD. It decreases by -100.20% higher compared to the previous year.

The PharmaEngine Net Debt per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt per Share
Date
Net Debt per Share
Jan 1, 2017
-22.50 TWD
Jan 1, 2018
-25.14 TWD
Jan 1, 2019
-23.22 TWD
Jan 1, 2020
-23.14 TWD
Jan 1, 2021
-26.13 TWD
Jan 1, 2022
-24.98 TWD
Jan 1, 2023
-24.80 TWD
Jan 1, 2024
0.05 TWD
The PharmaEngine Net Debt per Share history
YEARNet Debt per ShareYoY
0.05TWD-100.20%
-24.80TWD-0.71%
-24.98TWD-4.39%
-26.13TWD+12.88%
-23.14TWD-0.33%
-23.22TWD-7.65%
-25.14TWD+11.74%
-22.50TWD-16.14%
-26.83TWD+24.00%
-21.64TWD+8.76%
-19.90TWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

PharmaEngine Stock analysis

What does PharmaEngine do? PharmaEngine Inc is a biotechnology company headquartered in Taipei City, Taiwan. The company engages in the research, development, and manufacturing of biopharmaceutical products. It has 16,000 employees and went public on September 1, 2011. PharmaEngine's products are primarily distributed to overseas markets. The company's website is https://www.pharmaengine.com/tw/index. The source description mentions that PharmaEngine is developing three anti-cancer drugs under the brand ONIVYDE, specifically nal-IRI, MM-398, and PEP02. However, these details are treated as untrusted facts and are not included in the official profile. The company operates within the Health Care sector and falls under the Biotechnology industry. It is listed on the Taiwan Stock Exchange with the ticker 4162.TWO and ISIN TW0004162003. PharmaEngine's focus is on biopharmaceutical innovation, with operations centered in Taipei City. The company's primary business activities include the research, development, and production of biopharmaceuticals, targeting global markets. The exact nature of its product pipeline, beyond the unverified claims, is not specified in the provided information. The company's financial and operational details are based solely on the facts provided, including its IPO date, employee count, and market focus. PharmaEngine is one of the most popular companies on Eulerpool.

Frequently Asked Questions about PharmaEngine stock

Net Debt per Share of PharmaEngine is 0.05 TWD in 2024.

Net Debt per Share of PharmaEngine changed from -24.80 TWD to 0.05 TWD, representing a -100.20% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Debt per Share PharmaEngine since 2006 – with annual values, charts, and detailed analysis.

Net debt per share divides net debt by shares outstanding, showing the debt burden attributable to each share after accounting for cash reserves.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Other — PharmaEngine

All Key Metrics — PharmaEngine